Last week, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) made history. Over a span of two days—July 23rd and 24th— the committee reviewed seven peptides and voted to recommend six of them for inclusion on the FDA’s Section 503A Bulk Drug Substances List.
Could this move signal a turning point in how compounded peptides are regulated in the United States?
Here’s what happened, what it means, and what the evidence says about each of the peptides under review.
What Is PCAC and Why Does Its Recommendation Matter?
The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk drug substances (i.e. ingredients not commercially available as FDA-approved finished drugs) can be used by Section 503A compounding pharmacies (i.e. patient-specific compounding pharmacies that produce customized medications for individual patients under a licensed physician’s prescription).
To be added to the 503A Bulk Substances List, a substance must satisfy three criteria:
- There has to be a clinical need.
- The substance must be used to treat a condition that cannot adequately be addressed by an FDA-approved drug.
- The expected benefits have to outweigh the risks.
The July meeting was consequential because these seven peptides have occupied a regulatory gray area for years, with no pathway to legal access since the FDA restricted bulk peptide access in 2023.
How the Committee Voted
The vote was to recommend that six of the seven peptides under consideration be added to the Bulk Substances List.
Notably, the committee voted against the FDA’s own scientists (who had recommended against adding all seven peptides to the list).
The Gray Market Problem
To understand why the committee voted the way it did—overruling its own agency’s scientists—it’s essential to understand what has been happening in the absence of a regulated compounding pathway. The summary is that patient safety drove the vote.
Since the FDA restricted bulk peptide compounding in 2023, patients who rely upon these compounds for their health and wellbeing have not stopped using them. They have simply gone underground to unregulated sources. A sprawling gray market has emerged to fill the gap that was left by the FDA’s restrictions.
Chinese Suppliers
A significant portion of the gray market consists of peptides sold by Chinese chemical manufacturers through websites, social media, and cryptocurrency transactions—entirely outside the reach of U.S. regulatory oversight. Google searches for “Chinese peptides” increased by roughly 300-fold between January of 2025 and January of 2026, signally the explosive demand flowing through these channels with no regulatory guardrails.
The FDA’s own briefing documents acknowledged the scale of this market, noting that consumers are currently obtaining peptides that are “substantially produced with active ingredients largely sourced through an online Chinese gray market.” The agency also flagged several of the chemical firms supplying these ingredients as having previously been implicated in illegal fentanyl precursor production before pivoting to the peptide market—a detail that did not go unnoticed by the committee.
Domestic “for Research Purposes Only” Suppliers
Parallel to Chinese gray market imports, a domestic gray market has flourished—and it operates through a legal fiction that the FDA has been increasingly unwilling to accept.
Hundreds of U.S.-based vendors sell peptides under the label “for research purposes only” or “not for human use.” These disclaimers are designed to skirt FDA regulations by positioning the product as a laboratory reagent, rather than a pharmaceutical. These vendors often look like reputable businesses, with polished websites and scientific product descriptions.
However, the regulatory fiction collapses under scrutiny. The FDA has made it clear that the “research use only” label does not insulate these vendors if the totality of evidence indicates human use is the intended purpose. As one FDA analysis put it, a disclaimer that a compound is “for research use only” is not particularly persuasive when the evidence clearly points to human consumption.
What Gray Market Peptides Actually Contain
The safety profile of unregulated peptide products is alarming. Analysis of gray market peptide samples has found:
- 17% contain detectable heavy metals, including lead, cadmium, and mercury—compounds that accumulate within tissue and cause organ damage and neurotoxicity with repeated exposure.
- 65% exceed endotoxin safety thresholds—meaning they contain bacterial byproducts that, when injected, can trigger systemic inflammatory responses ranging from fever to sepsis.
- Up to 40% contain incorrect dosages or undeclared ingredients, based upon FDA spot-check analyses of these products.
- Purity discrepancies are endemic, with products frequently containing degradation byproducts, incorrect protein sequences, or entirely different compounds than labeled.
Unlike FDA-regulated pharmaceutical manufacturers and compounders, Chinese and research peptide producers operate outside of regulatory oversight. There is no mandatory batch testing, no chain of custody documentation, no requirement for sterility validation, and no mechanism for recall when contaminated products are identified. Patients who purchase these products have no reliable way of knowing what they are actually injecting into their bodies.
Harm Reduction as a Regulatory Argument
This context became central to the committee’s deliberations. Several committee members explicitly invoked harm reduction logic in their rationale for supporting inclusion on the bulk list:
If patients are going to use these peptides regardless of regulatory status, the question is not whether they will access them, but how. Will it be through licensed 503A pharmacies operating under state board oversight, USP standards, and compounding pharmacy regulations? Or will it be through gray market suppliers with no accountability whatsoever?
The argument is fairly straightforward. A patient accessing BPC-157 through a licensed compounding pharmacy receives a product with verified purity, accurate dosing, documented sterility, and a prescribing physician’s oversight. The same patient purchasing from the gray market receives an unknown substance in an unmarked vial, without physician oversight, and with no recourse if it causes harm.
One committee member characterized the dilemma thusly:
The status quo—maintaining restrictions while the gray market expands—does not protect patients.
The committee’s willingness to accept this argument, despite opposition from FDA staff scientists, reflects a pragmatic recognition that regulatory policy has real-world behavioral consequences. Restrictions that drive demand underground don’t eliminate risk—they simply concentrate it within the riskiest supply chain.
What This Vote Means
It’s important to understand what the PCAC vote does, and also what it doesn’t do.
The committee’s recommendations are strictly advisory. In other words, they do not immediately change what compounding pharmacies can or cannot legally compound. The FDA still has to decide whether or not to act on these recommendations. Doing so requires a formal notice-and-comment rulemaking process, which includes: a proposed rule, a public comment period, and then a final rule. Regulatory experts estimate this process could extend into 2027.
In the meantime, reputable compounding pharmacies are unlikely to treat this vote as authorization to resume production of unrestricted peptides.
With that said, the committee’s vote does signal meaningful momentum. Specifically, it sets the table for the regulatory updates that hopefully lie ahead.
The Six Recommended Peptides
1. BPC-157
Proposed indications: Ulcerative colitis, gastrointestinal healing, inflammatory bowel conditions, healing (of tendons, ligaments, muscle, and bone), and reduced inflammation.
BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found within human gastric fluids. It is perhaps the most extensively researched peptide in the group, with over 100 peer-reviewed studies. The majority of these studies is focused on gastrointestinal repair.
BPC-157’s mechanism is well-characterized. It promotes healing of the GI tract through multiple pathways by:
- Increased blood flow to damaged tissue.
- Reduced inflammatory cytokine production.
- Enhanced mucus secretion.
- Upregulated tight-junction proteins that maintain intestinal barrier integrity.
In animal models of ulcerative colitis, Crohn’s disease, NSAID-induced gut damage, and alcohol-induced ulceration, BPC-157 consistently reduced inflammation and accelerated structural repair.
Beyond GI applications, BPC-157 has been shown to accelerate healing of tendons, ligaments, muscles, and bone in preclinical models. There is also evidence of it providing neurological benefits and systemic anti-inflammatory effects.
The evidence base is substantial, but no large-scale, placebo-controlled human trials have been published. The committee’s vote reflects the depth of preclinical data and the significant unmet need when it comes to treating conditions like ulcerative colitis (where existing treatments carry serious side effects and remission rates remain suboptimal).
2. KPV (Lysine-Proline-Valine)
Proposed indications: Inflammatory bowel conditions, ulcerative colitis, and inflammatory skin conditions.
KPV is a tripeptide, consisting of three amino acids (lysine, proline, and valine). These three amino acids in combination are a fragment of a hormone called alpha-melanocyte stimulating hormone (α-MSH). KPV retains the full anti-inflammatory potency of its parent hormone, but without triggering the skin-darkening effects associated with melanocortin signaling.
What makes KPV particularly compelling for reduction of gut inflammation is its delivery mechanism. KPV is actively transported into inflamed intestinal cells via a transporter that self-upregulates in inflamed tissue. This means KPV effectively targets itself to the sites where it is most needed, making oral delivery viable for inflammatory bowel applications.
Mechanistically, KPV inhibits two of the most important intracellular signaling pathways active in inflammatory bowel disease (IBD) pathology: the NF-κB cascade and the MAPK pathway (both of which drive the production of pro-inflammatory cytokines). Published research demonstrated that oral KPV reduced colitis severity by over 50% in mouse models.
No human clinical trials have been conducted, but two decades of preclinical research provide a strong case. KPV’s proposed use fills a significant therapeutic gap because it provides a targeted, low-toxicity oral anti-inflammatory for IBD patients who cannot tolerate or are unresponsive to other therapies.
3. TB-500
Proposed indications: Wound healing, musculoskeletal injury recovery, and tissue repair.
TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring protein present within virtually every cell in the body. Thymosin Beta-4 plays a foundational role in tissue maintenance, with TB-500 being developed to replicate its most therapeutically active fragment.
The evidence for TB-500’s wound healing properties is among the strongest of any peptide in this review. The mechanism involves three complementary actions:
- Angiogenesis (which promotes the formation of new blood vessels to deliver oxygen and nutrients to the injury site).
- Cell migration (which recruits fibroblasts and keratinocytes to rebuild damaged tissue).
- Anti-inflammatory modulation (that creates a healing-permissive environment, while preventing excessive scarring).
In preclinical models of skin wounds, muscle crush injuries, tendon tears, and cardiac ischemia (i.e. damage from a blockage), TB-500 consistently accelerates functional recovery, improves tissue architecture, and reduces fibrotic scarring.
Phase II clinical trials have shown accelerated wound closure in chronic and acute skin wounds, providing some of the most direct human data supporting its use.
TB-500 also activates satellite cells—which are the stem-cell-like progenitors responsible for muscle fiber regeneration—making it particularly relevant for sports medicine, post-surgical recovery, and chronic wound management. Its long history of use in compounding pharmacies before the 2023 restrictions, combined with its favorable safety profile, likely contributed to the committee’s recommendation.
4. MOTS-c
Proposed indications: Obesity, insulin resistance, metabolic syndrome, and osteoporosis.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is biologically unlike any other peptide in this group. It is encoded within mitochondrial DNA—not nuclear DNA—making it one of the only known mitochondria-derived signaling peptides in humans (which points to its fundamental role in cellular energy regulation).
MOTS-c’s primary mechanism involves activation of AMPK (AMP-activated protein kinase), sometimes called the “metabolic master switch.” When AMPK is activated, it drives upregulation of glucose transporters in skeletal muscle, improving insulin-mediated glucose uptake, independent of conventional insulin signaling pathways. In high-fat diet mouse models, MOTS-c dramatically reduced insulin resistance, improved glucose tolerance, and prevented obesity.
Naturally circulating levels of MOTS-c decline with age, with low levels being inversely correlated with insulin resistance. This points to MOTS-c’s physiological role in maintaining metabolic homeostasis, making it a compelling candidate for treating metabolic disease.
A Phase 2a clinical trial began recruiting in February of 2026 to evaluate MOTS-c in adults. This is the most advanced human trial for any peptide in this cohort.
5. Semax
Proposed indications: Cerebral stroke (ischemia), migraine, trigeminal neuralgia, and cognitive function.
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH (adrenocorticotrophic hormone). It has been in clinical use in Russia since the 1990s, where it is approved for the treatment of stroke and transient ischemic attack—giving it the most substantial clinical track record of any peptide in this review.
Its primary mechanism is upregulation of brain-derived neurotrophic factor (BDNF), which plays a central role in neuronal survival, synaptic plasticity, and recovery from brain injury. Semax also modulates dopaminergic and serotonergic neurotransmission and demonstrates direct neuroprotective effects in models of ischemic and oxidative neuronal injury.
Russian clinical trials—which were acknowledged in the committee’s briefing materials—demonstrate efficacy in acute stroke management and cognitive rehabilitation post-ischemia. The committee cited these data, along with the unmet clinical need in acute cerebrovascular conditions, as being central to its recommendation.
In the United States, Semax is primarily studied and used for cognitive support, migraine management, and neurological recovery. While evidence for cognitive enhancement in otherwise healthy adults is limited, the neuroprotective evidence for ischemic conditions is among the stronger clinical datasets in this group.
6. Epitalon
Proposed indications: Insomnia, circadian rhythm disruption, and age-related conditions.
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide that is an analogue of epithalamin, a natural peptide produced by the pineal gland that is involved in regulating circadian rhythm and melatonin production.
Epitalon’s most widely studied mechanism is activation of telomerase, the enzyme responsible for maintaining telomere length. Telomere shortening is one of the hallmarks of cellular aging, and Epitalon has been shown to elongate telomeres in human cell cultures and in some animal studies—a finding that has made it a subject of significant interest in longevity research.
Beyond telomere biology, Epitalon has been shown to normalize disrupted circadian rhythm, improve sleep architecture, reduce oxidative stress markers, and regulate neuroendocrine effects (including restoration of age-related melatonin decline). Russian research has also documented anti-tumor properties and improved immune function in animal models.
Human clinical evidence remains limited, and the committee acknowledged this in its deliberations. However, the unmet clinical need in age-related insomnia and circadian disruption—conditions that are poorly managed by existing pharmacological options and carry significant long-term health consequences—weighed in favor of the recommendation.
The Peptide the Committee Rejected
Delta Sleep-Inducing Peptide (DSIP) was the only peptide the committee declined to recommend. DSIP is a nonapeptide that was originally identified for its sleep-promoting properties. It has also been studied for stress modulation and neuroendocrine regulation.
The committee’s concerns centered on thinner and less consistent preclinical evidence compared to the other peptides reviewed, along with unresolved questions about stability and bioavailability.
The vote was close enough that future data could prompt reconsideration; but for now, DSIP remains off the recommended list.
What This Means for Patients
For patients who have relied upon compounded peptides for conditions ranging from inflammatory bowel disease to metabolic dysfunction to neurological recovery, the PCAC’s vote is good news. However, the vote requires context.
The six favorable recommendations do not restore immediate access to these peptides. They do, however, initiate a formal regulatory process that, if completed, will provide a compounding pathway that will be clear, legal, and safe.
The committee’s willingness to overrule its own agency’s scientists reflects a genuine recognition of unmet clinical needs, and also of the risk associated with patients accessing the gray market. The ball is now in the FDA’s court.
At Renew Youth, we prioritize patient safety above all else. Are you confused about the status of peptide therapy in the United States? Call us. We can tell you which peptides are available through safe and legal channels, versus which ones are not. We can be reached at (800) 859-7511 or use our easy contact form to schedule your complimentary 30-minute consultation.